Skip to Main Content

Paper Details

Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Cancer Res Commun
1
2022
DLL3, DLL3 mRNA, DLL3 protein, Neuroblastomas, PBD, PDX, RNA sequencing, Rova-T, Wilms and rhabdoid tumors, childhood, delta-like ligand 3, human, human neuroblastoma, neuroblastoma, neuroblastoma PDX array, neuroblastoma PDX models, neuroblastoma patient derived xenograft, patient, pyrrolobenzodiazepine, rovalpituzumab, rovalpituzumab tesirine, small cell lung cancer, tumor, tumors
Author NameAffiliation
Kateryna KrytskaDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
Jennifer PogorilerPerelman School of Medicine at the University of Pennsylvania
Jennifer PogorilerPerelman School of Medicine at the University of Pennsylvania
Daniel MartinezPerelman School of Medicine at the University of Pennsylvania
Daniel MartinezPerelman School of Medicine at the University of Pennsylvania
Komal S RathiDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
Komal S RathiDepartment of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine Children's Hospital of Philadelphia
Komal S RathiDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
Komal S RathiDepartment of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine Children's Hospital of Philadelphia
Alvin FarrelDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
Alvin FarrelDepartment of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine Children's Hospital of Philadelphia
Esther R BerkoDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
Nathan M KendserskyDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
Malcolm A Smith
Malcolm A Smith
John M MarisDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
John M MarisPerelman School of Medicine at the University of Pennsylvania
John M MarisDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
John M MarisPerelman School of Medicine at the University of Pennsylvania
Yael P MosseDivision of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia
Yael P MossePerelman School of Medicine at the University of Pennsylvania
  • 1 - 21

Datasets

Release 1.2